Tethis launches See.d®, the first fully automated and standardized pre-analytical platform for comprehensive liquid biopsy testing

Seed® is intended for professional use but does not require specialized laboratory technicians and, above all, there is no need for shipping and storing whole blood, one of the most critical points of pre- liquid biopsy analysis. Seed® processes fresh blood collected in EDTA tubes soon after collection (within 4-6 hours) promoting maximum sample integrity. All sample preparation steps are automated: separation of plasma from the cellular fraction, lysis and elimination of red blood cells, distribution and fixation of white blood cells on SBS slides and recovery of plasma in tubes. At the end of the process, SBS slides with a fixed monolayer of all white blood cells are made available, and the relative plasma aliquot is provided in a separate tube. Both specimens are perfectly stable for several days, having undergone minimal handling, contamination or shear stress before stabilization.

The platform will be presented at the next liquid biopsy conference organized by the European Association for Cancer Research (EACR) in Bergamo, Italyfrom May 24and at 26and.

“This is a key development milestone not only for Tethis but hopefully for the adoption of liquid biopsy,” Mr. Gian Martino Franchi, chief technology officer of the company. “We relied on our proprietary nano-coated slides that allow immediate, spontaneous and gentle adhesion of normally non-adherent cells, to develop a fully automated platform that not only attaches all white blood cells for rare cell detection without enrichment, but also provides a perfect stable plasma fraction for cell-free content analysis, allowing for optimal preparation of all relevant content for liquid biopsy testing.This is a first of its kind, and we are convinced that it can contribute to the long-awaited standardization of blood processing for liquid biopsies.We have worked closely with our partner MACS srl for the development of this first version, and we have already started planning the platform. -next generation shape that will further improve ease of use, efficiency and throughput”

SBS slides are compatible with all analytical pathology techniques, including cytology, immunocytochemistry (ICC), immunofluorescence (IF), fluorescence in situ hybridization (FISH), for morphological and based analysis on biomarkers by acquisition of brightfield or fluorescence images. Highly efficient cell adhesion and preserved morphology, together with the optimal distribution of cells on slides as a monolayer, enables the implementation of AI-supported digital imaging for detection, classification and automated and efficient profiling of rare circulating tumor cells as well as the immune cell compartment. Additionally, identified cells can be recovered by microdissection for downstream molecular analysis at the single-cell level.

Plasma, on the other hand, is stable for several days without the need for freezing and ready for cfNA extraction without further centrifugation steps. Simplified, automated processing delivers uncontaminated, standardized plasma for reproducible, high-quality downstream analysis of cell-free content.

“We are excited to bring this new solution to market,” said Ms. Roberta Carbone, Ph.D, scientific director of Tethis. “This is a first step towards true standardized multi-analytical liquid biopsy tests involving all possible tumor contents released into the bloodstream. We are currently working on validating the platform’s CE-IVD mark and developing new tests of liquid biopsy to bring to patients and those at risk, but we also welcome diagnostic industry players and drug developers who wish to exploit the optimal and complete preparation guaranteed by See.d® for the development of new companion tests and diagnostics or for patient stratification in clinical trials”

Seed® and SBS slides are for research use only, not for diagnostic procedures.

Tethis SpA is based in Milan, Italy, and develops a new workflow to integrate liquid biopsy into clinical practice for the precise management of cancer. Tethis’ technology emphasizes the standardization of blood sample preparation to provide the highest quality and integrity of liquid biopsy specimens for comprehensive analysis of all clinically relevant biomarkers. The company’s proprietary nano-coated slides, combined with the automated pre-analytical instrument, can identify and characterize rare cells in the blood, such as circulating tumor cells, with unprecedented sensitivity, also at an early stage. early.

Further information is available on the company’s website, www.tethis-lab.com.

Photo – https://mma.prnewswire.com/media/1818232/Tethis_1.jpg
Logo – https://mma.prnewswire.com/media/1818233/Tethis_Logo.jpg